Abstract
Background : Metaplastic Breast Cancer (MpBC) is an exceedingly
rare entity, accounting for less than 1% of all malignant breast
tumours. Predominantly triple-negative, they are notorious for their
chemoresistance, high rates of recurrence and decreased disease-free
survival (DFS). All this contributes significantly to BC mortality and
results in poor prognostic implications. Limited evidence has led to a
lacuna of specific treatment guidelines for this entity and hence
remains an uncharted territory for clinicians.
Case : We report a case of left-sided low-grade metaplastic
triple negative T3N2aM0 BC treated with neoadjuvant chemotherapy,
primary surgery, and adjuvant radiotherapy, presently in remission.
Conclusion : Limited experience in management of this
pathological entity warrants the need for more research on it, with a
special focus on targeted therapy. Discussing possibilities of a
tailored approach, rather than a one-size-fits-all approach may aid in
paving the path for the future of MpBC treatment.